Eyeglasses and contact lenses: Medicare will not pay for eyeglasses or contact lenses, with one exception: If you have had a ...

- Cash Position: Cash and cash equivalents were $101.6 million as of March 31, 2025, compared to $34.6 million as of December 31, 2024, bolstered by $76.4 million in gross proceeds from the first ...

Researchers have discovered in an ongoing phase IIb trial that a single intravitreal injection of UBX1325 (foselutoclax), a ...

At the ARVO 2025 Annual Meeting in Salt Lake City, Utah, Nimesh Patel, MD, presented on the LUCIA and LUGANO phase 3 pivotal ...

Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies ...

Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for ...

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in ...

A potential game changer in the treatment of retinal disease, the novel dual-target drug shows encouraging results.

Aiming to enhance the eye care treatment, Sealdah Division of Eastern Railway has introduced Advanced OCT-A Technology at BR Singh Hospital.

TheyaVue markets itself as a supportive tool in this environment, offering a bioavailable, antioxidant-rich formula that ...

Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...